NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Forecast, Price & News $64.66 +0.81 (+1.27%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$62.90▼$65.5050-Day Range$43.14▼$67.7752-Week Range$38.94▼$86.95Volume1.02 million shsAverage Volume1.23 million shsMarket Capitalization$5.10 billionP/E RatioN/ADividend YieldN/APrice Target$74.89 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CRISPR Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside15.8% Upside$74.89 Price TargetShort InterestHealthy16.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 18 Articles This WeekInsider TradingSelling Shares$2.38 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.61) to ($5.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector490th out of 1,010 stocksBiological Products, Except Diagnostic Industry75th out of 169 stocks 3.3 Analyst's Opinion Consensus RatingCRISPR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 10 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.89, CRISPR Therapeutics has a forecasted upside of 15.8% from its current price of $64.66.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.42% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 5.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRSP. Previous Next 2.8 News and Social Media Coverage News SentimentCRISPR Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for CRISPR Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 71 people have searched for CRSP on MarketBeat in the last 30 days. This is a decrease of -1% compared to the previous 30 days.MarketBeat FollowsOnly 19 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -34% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,378,250.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions71.51% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($6.61) to ($5.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CRISPR Therapeutics (NASDAQ:CRSP) StockCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Read More Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Stock News HeadlinesMay 18, 2023 | marketbeat.comVertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (CRSP)Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.May 25, 2023 | benzinga.comCRISPR Therapeutics Stock (NASDAQ:CRSP), Short Interest ReportMay 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 25, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for CRISPR Therapeutics AG (NASDAQ:CRSP) Issued By Zacks ResearchMay 25, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6.8% Following Analyst UpgradeMay 24, 2023 | msn.comCitigroup Maintains CRISPR Therapeutics (CRSP) Neutral RecommendationMay 23, 2023 | benzinga.comCRISPR Therapeutics Unusual Options ActivityMay 23, 2023 | msn.comCRISPR Therapeutics Earnings Perspective: Return On Capital EmployedMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 23, 2023 | finance.yahoo.comCRISPR Therapeutics Stock Joins Rank Of Stocks With RS Ratings Over 90May 23, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $70.00 at CitigroupMay 19, 2023 | seekingalpha.comCrispr Therapeutics: Hold Until A Firmer Decision DateMay 18, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.3%May 17, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.3%May 16, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Crispr Therapeutics AG (CRSP)May 16, 2023 | americanbankingnews.comCantor Fitzgerald Weighs in on CRISPR Therapeutics AG's FY2023 Earnings (NASDAQ:CRSP)May 16, 2023 | realmoney.thestreet.comWhy Are CRISPR Therapeutics Charts Saying 'Buy'?May 15, 2023 | seekingalpha.comCRISPR Therapeutics AG (CRSP) JMP Securities Life Sciences Conference (Transcript)May 15, 2023 | seekingalpha.comCRISPR Therapeutics AG (CRSP) Presents at JMP Securities Life Sciences Conference (Transcript)May 14, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Upgraded at StockNews.comMay 14, 2023 | americanbankingnews.comChardan Capital Analysts Decrease Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP)May 13, 2023 | seekingalpha.comCRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)May 13, 2023 | seekingalpha.comCRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)May 13, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for CRISPR Therapeutics AG Issued By Brookline Capital Management (NASDAQ:CRSP)May 13, 2023 | americanbankingnews.comCRISPR Therapeutics' (CRSP) "Reiterates" Rating Reaffirmed at VNET GroupMay 12, 2023 | msn.comMorgan Stanley Maintains CRISPR Therapeutics (CRSP) Underweight RecommendationMay 12, 2023 | americanbankingnews.comEquities Analysts Set Expectations for CRISPR Therapeutics AG's FY2024 Earnings (NASDAQ:CRSP)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Company Calendar Last Earnings5/08/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP CUSIPN/A CIK1674416 Webwww.crisprtx.com Phone(141) 561-3277FaxN/AEmployees473Year FoundedN/APrice Target and Rating Average Stock Price Forecast$74.89 High Stock Price Forecast$123.00 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+15.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-650,170,000.00 Net Margins-516.43% Pretax Margin-525.28% Return on Equity-26.64% Return on Assets-22.26% Debt Debt-to-Equity RatioN/A Current Ratio13.00 Quick Ratio13.00 Sales & Book Value Annual Sales$100.26 million Price / Sales50.91 Cash FlowN/A Price / Cash FlowN/A Book Value$23.95 per share Price / Book2.70Miscellaneous Outstanding Shares78,935,000Free Float75,699,000Market Cap$5.10 billion OptionableOptionable Beta1.71 Key ExecutivesDr. Rodger Novak M.D. (Age 55)Founder, Chairman & Pres Dr. Samarth Kulkarni (Age 43)CEO & Director Comp: $1.18MDr. Lawrence Otto Klein Ph.D. (Age 40)Chief Operating Officer Comp: $675kMr. James R. Kasinger (Age 50)Gen. Counsel & Sec. Comp: $648.93kMr. Shaun FoyFounderDr. Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board MemberDr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board MemberDr. Chad Cowan Ph.D.Scientific FounderDr. Matthew Porteus M.D. (Age 56)Ph.D., Scientific Founder & Advisory Board Member Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board MemberMore ExecutivesKey CompetitorsVaxcyteNASDAQ:PCVXHalozyme TherapeuticsNASDAQ:HALODenali TherapeuticsNASDAQ:DNLIExelixisNASDAQ:EXELAbcamNASDAQ:ABCMView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,853 shares on 5/26/2023Ownership: 0.007%Front Row Advisors LLCSold 180 shares on 5/23/2023Ownership: 0.022%Capital Impact Advisors LLCBought 8,205 shares on 5/23/2023Ownership: 0.010%Ameriprise Financial Inc.Bought 25,994 shares on 5/22/2023Ownership: 0.106%Arete Wealth Advisors LLCBought 11,014 shares on 5/22/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions CRSP Stock - Frequently Asked Questions Should I buy or sell CRISPR Therapeutics stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRSP shares. View CRSP analyst ratings or view top-rated stocks. What is CRISPR Therapeutics' stock price forecast for 2023? 18 Wall Street research analysts have issued twelve-month target prices for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's stock price to reach $74.89 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts. How have CRSP shares performed in 2023? CRISPR Therapeutics' stock was trading at $40.65 on January 1st, 2023. Since then, CRSP stock has increased by 59.1% and is now trading at $64.66. View the best growth stocks for 2023 here. Are investors shorting CRISPR Therapeutics? CRISPR Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 12,430,000 shares, a decrease of 5.8% from the April 30th total of 13,200,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 9.5 days. Approximately 16.4% of the company's shares are sold short. View CRISPR Therapeutics' Short Interest. When is CRISPR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CRSP earnings forecast. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($1.64) by $0.97. The firm earned $100 million during the quarter, compared to analyst estimates of $24.33 million. CRISPR Therapeutics had a negative net margin of 516.43% and a negative trailing twelve-month return on equity of 26.64%. CRISPR Therapeutics's revenue was up 10538.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.32) earnings per share. What ETFs hold CRISPR Therapeutics' stock? ETFs with the largest weight of CRISPR Therapeutics (NASDAQ:CRSP) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Loncar Cancer Immunotherapy ETF (CNCR), Global X Genomics & Biotechnology ETF (GNOM), AXS Green Alpha ETF (NXTE), iShares Genomics Immunology and Healthcare ETF (IDNA) and Horizon Kinetics Medical ETF (MEDX). What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP). When did CRISPR Therapeutics IPO? (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is CRISPR Therapeutics' stock symbol? CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." Who are CRISPR Therapeutics' major shareholders? CRISPR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (10.16%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), Nikko Asset Management Americas Inc. (5.04%), BlackRock Inc. (3.55%), FMR LLC (2.71%) and State Street Corp (2.52%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CRISPR Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $64.66. How much money does CRISPR Therapeutics make? CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $5.10 billion and generates $100.26 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis. How many employees does CRISPR Therapeutics have? The company employs 473 workers across the globe. How can I contact CRISPR Therapeutics? CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com. This page (NASDAQ:CRSP) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.